This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease


Beglinger, Leigh J., Adams, Williams H., Paulson, Henry, Fiedorowicz, Jess G., Langbehn, Douglas R., Duff, Kevin, Leserman, Anne, Paulsen, Jane S.


Journal Of Clinical Psychopharmacology, Volume: 29, No.: 5, Pages.: 484-487

Year of Publication



Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive atomoxetine (80 mg/d) or placebo in a 10-week double-blind crossover study. Primary outcome measures were self-reported attention and attention and executive neuropsychological composite scores. Secondary outcomes were psychiatric and motor symptom scores.; Results: The rate of reported adverse effects while on atomoxetine was 56% (vs 35% on placebo), which most commonly included dry mouth (39%), loss of appetite (22%), insomnia (22%), and dizziness (17%). There were no serious adverse events related to atomoxetine. There were statistically significant, although mild, increases in heart rate and diastolic blood pressure on atomoxetine, consistent with other studies and not requiring medical referral. There were no significant improvements while on atomoxetine compared with placebo on primary outcomes. However, there was evidence of significant placebo effects on self-reported attention and psychiatric functions. There were no group differences on the Unified Huntington’s Disease Rating total motor score.; Conclusions: Atomoxetine demonstrated no advantages over placebo for primary or secondary outcomes. Although atomoxetine was not effective at improving attention at this dose, its safety and tolerability were similar to other studies.;

Bibtex Citation

@article{Beglinger_2009, doi = {10.1097/jcp.0b013e3181b2ac0a}, url = {}, year = 2009, month = {oct}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {29}, number = {5}, pages = {484--487}, author = {Leigh J. Beglinger and Williams H. Adams and Henry Paulson and Jess G. Fiedorowicz and Douglas R. Langbehn and Kevin Duff and Anne Leserman and Jane S. Paulsen}, title = {Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease}, journal = {Journal of Clinical Psychopharmacology} }


adult, atomoxetine, cognition disorders, complications, double-blind method, drug therapy, etiology, female, humans, huntington disease, male, middle aged, pilot projects, propylamines, psychology, therapeutic use, time factors, young adult

Countries of Study


Types of Dementia


Types of Study

Case Control Study

Type of Outcomes

Cognition, Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions